Findings

What do systematic reviews say?

149 questions · 157 findings · 43 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 2.5%GRADE not reported 6 · 3.8%Very low 10 · 6.4%Low 71 · 45.2%Moderate 48 · 30.6%High 18 · 11.5%

Intervention vs usual care

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Intervention vs usual care

Quality of life ‐ CAT · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Low

Breathing exercises vs inactive control

Asthma control · adults with asthma

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Low

Breathing exercises vs inactive control

Nijmegen questionnaire · adults with asthma

1 finding from 1 review

Breathing exercises for adults with asthma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 118 participants
Moderate

Corticosteroids vs placebo

AHI · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Low

Corticosteroids vs placebo

Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Moderate

Montelukast vs placebo

AHI · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 103 participants
Moderate

Montelukast vs placebo

Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 103 participants
High

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Benralizumab 10 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 680 participants
Moderate

Benralizumab 30 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1333 participants
Moderate

Benralizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1433 participants
High

Benralizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1351 participants
High

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Mepolizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1285 participants
Moderate

Myofunctional therapy plus nasal washing vs Nasal washing alone

AHI score reduction to below 5 points. · obstructive sleep apnoea

Myofunctional therapy plus nasal washing showed no clear difference in AHI score reduction to below 5 points. compared with nasal washing alone (low certainty).

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
OR 12.5 [0.84, 186.3]
1 study · 13 participants
Low

Mucolytic vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD

1 finding from 1 review

Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2721 participants
Moderate

Positional therapy vs inactive control

Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea

1 finding from 1 review

Positional therapy for obstructive sleep apnoea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Positional therapy vs continuous positive airway pressure (CPAP)

Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea

1 finding from 1 review

Positional therapy for obstructive sleep apnoea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported